Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, Achim; Barlesi, Fabrice; Waterkamp, Daniel; Park, Keunchil; Ciardiello, Fortunato; von Pawel, Joachim; Gadgeel, Shirish; Hida, Toyoaki; Kowalski, Dariusz; Dols, Manuel; Cortinovis, Diego; Leach, Joseph; Polikoff, Jonathan; Barrios, Carlos; Kabbinavar, Fairooz; Frontera, Osvaldo; De Marinis, Filippo; Turna, Hande; Lee, Jong-Seok; Ballinger, Marcus; Kowanetz, Marcin; He, Pei; Chen, Daniel; Sandler, Alan; Gandara, David

doi:10.1016/s0140-6736(16)32517-x

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., ...Daha Fazla

LANCET, cilt.389, sa.10066, ss.255-265, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 389 Sayı: 10066
Basım Tarihi: 2017
Doi Numarası: 10.1016/s0140-6736(16)32517-x
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.255-265
İstanbul Üniversitesi Adresli: Evet

Özet

Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.